These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19647893)

  • 1. [Treatment of liver fibrosis].
    Domínguez M; Colmenero J; Bataller R
    Gastroenterol Hepatol; 2009 Nov; 32(9):627-32. PubMed ID: 19647893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fibrosis: from the bench to clinical targets.
    Pinzani M; Rombouts K
    Dig Liver Dis; 2004 Apr; 36(4):231-42. PubMed ID: 15115333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
    Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
    Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Liver fibrosis: pathophysiology, diagnosis and treatment].
    Pár A; Pár G
    Orv Hetil; 2005 Jan; 146(1):3-13. PubMed ID: 15715367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of liver fibrosis: clinical aspects.
    Calès P; Boursier J; Chaigneau J; Oberti F; Rousselet MC
    Gastroenterol Clin Biol; 2009; 33(10-11):958-66. PubMed ID: 19717256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic risk factors for hepatic fibrosis in chronic liver diseases].
    Wasmuth HE; Lammert F; Matern S
    Med Klin (Munich); 2003 Dec; 98(12):754-62. PubMed ID: 14685677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic.
    Muddu AK; Guha IN; Elsharkawy AM; Mann DA
    Int J Biochem Cell Biol; 2007; 39(4):695-714. PubMed ID: 17110155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
    Ekstedt M; Franzén LE; Holmqvist M; Bendtsen P; Mathiesen UL; Bodemar G; Kechagias S
    Scand J Gastroenterol; 2009; 44(3):366-74. PubMed ID: 19016382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of NAFLD.
    Trappoliere M; Tuccillo C; Federico A; Di Leva A; Niosi M; D'Alessio C; Capasso R; Coppola F; Dauria M; Loguercio C
    Eur Rev Med Pharmacol Sci; 2005; 9(5):299-304. PubMed ID: 16231594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C and liver fibrosis.
    Schuppan D; Krebs A; Bauer M; Hahn EG
    Cell Death Differ; 2003 Jan; 10 Suppl 1():S59-67. PubMed ID: 12655347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy for hepatic fibrosis.
    Brenner DA; Alcorn JM
    Semin Liver Dis; 1990 Feb; 10(1):75-83. PubMed ID: 2186490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrosis and disease progression in hepatitis C.
    Marcellin P; Asselah T; Boyer N
    Hepatology; 2002 Nov; 36(5 Suppl 1):S47-56. PubMed ID: 12407576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
    Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical application of non-invasive diagnosis for hepatic fibrosis].
    Cho SW; Cheong JY
    Korean J Hepatol; 2007 Jun; 13(2):129-37. PubMed ID: 17585186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002.
    Schiavini M; Angeli E; Mainini A; Zerbi P; Duca PG; Gubertini G; Vago L; Fociani P; Giorgi R; Cargnel A
    HIV Med; 2006 Jul; 7(5):331-7. PubMed ID: 16945079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.
    Hézode C; Roudot-Thoraval F; Nguyen S; Grenard P; Julien B; Zafrani ES; Pawlotsky JM; Dhumeaux D; Lotersztajn S; Mallat A
    Hepatology; 2005 Jul; 42(1):63-71. PubMed ID: 15892090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
    Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests.
    Gressner OA; Weiskirchen R; Gressner AM
    Clin Chim Acta; 2007 Jun; 381(2):107-13. PubMed ID: 17399697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic stellate cells and the reversal of fibrosis.
    Kisseleva T; Brenner DA
    J Gastroenterol Hepatol; 2006 Oct; 21 Suppl 3():S84-7. PubMed ID: 16958681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.